MBC BioLabs Announces Celgene Partnership and "Golden Ticket"
We are delighted to announce a partnership with Celgene Corporation to support promising entrepreneurial scientists. A key feature of this program will be the Celgene "Golden Ticket" awards for promising startups. These Golden Tickets provide priority admission and lab-space at MBC BioLabs for a scientist for a year. Participants in this program will also have the opportunity to work with and receive mentorship from the Celgene team on drug discovery and development.
With a strong commitment to delivering innovative and life-changing medicines, Celgene focuses on the discovery, development, and commercialization of products for the treatment of cancer, immune, neurodegenerative, and other severe conditions. For more information and how to apply, please visit the MBC BioLabs website.
Enable Biosciences Inc. has been awarded a two-year National Institutes of Health/National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK) Small Business Innovation Research (SBIR) Phase II grant for $1.5 million to commercialize innovative technology by conducting research and development (R&D) work on low cost and multiplex tests for type 1 diabetes. Full Press Release
Capitalizing on over 20 years of structural genomics and structural biology expertise using high-throughput protein X-ray crystallography, Accelero Biostructures uses its ABSTM and ABS-OneStepTM platforms for structure-based drug discovery and protein engineering. ABSTM provides a unified pipeline for protein X-ray crystallography and structural biology to pharmaceutical and biotechnology companies to support structure-based drug discovery.
CAGE Biosciences Inc. is focused on developing novel and valuable products for dermatology. Our mission is to minimize the pervasive use of systemic drugs for the treatment of dermal diseases and symptoms. CAGE's lead product is based on Ionic Liquid technology in-licensed from Prof. Samir Mitragotri's laboratory at the University of California, Santa Barbara. Ionic Liquids offer broad spectrum antimicrobial and anti-inflammatory properties along with enhancement of solubility and permeability. These properties combined with excellent biocompatibility make them attractive as and for formulating effective products for dermatology.
Dahlia Biosciences is developing CRISPR-Cas9 enabled nucleic acid detection tools for cell and tissue analysis.
Fountain Therapeutics is discovering and developing treatments for aging-associated diseases. We have built a transformative model of aging that re-creates many of the complex hallmark features of aging, but in a laboratory dish. We are combining this powerful cellular model with the latest in artificial intelligence and computer vision to develop a disruptive unbiased platform for the identification of novel targets and potential therapeutics. We work toward our vision of a future in which we extend healthy lifespan and slow aging itself.
Exponentially better health requires examination and integration of omics, clinical, and behavioral data to create personalized plans of action for measurable outcomes. Using machine learning, January will synthesize personal data with our expertise in systems biology to put control back in the hands of individuals who seek optimal performance and productivity.
RubrYc Therapeutics is a discovery-stage therapeutic antibody business focused on addressing unmet needs in Oncology and Autoimmune Diseases. The Company was founded in 2017 and launched earlier this year with a $10M Series A Preferred financing. RubrYc has developed the Interface Discovery Engine – the operating system the Company employs to realize critical efficiency gains in drug discovery. RubrYc maintains intense focus on advancing its proprietary pipeline programs, while engaging in target-specific Platform Partnerships with industry incumbents.
Synimmune Inc. is a biotechnology company aiming to commercialize our company's own immune-oncology products as well as providing R&D services to partner companies that develop immunotherapies to treat patients with cancer. The company's Monoclonal TCR Technology facilitate the generation of novel tumor specific TCRs for the development of adoptive T cell therapy. The company's Antigen Discovery Platform enable functional identification of neoantigens for the development of personalized cancer vaccines.
Seminar: Ai Ching Lim, PhD, Director of Therapeutic Discovery Research, Amgen Unlocking the potential of biology for patients
Ai Ching leads the protein technologies groups at Amgen SSF
To be followed by happy hour, Register
September 13, 2018, 3:00 PM